Phosphodiesterase-5 (PDE-5) inhibitors induces vasodilation in several organs by blocking cyclic GMP (guanosine monophosphate) degradation. However, the existence of alternative mechanism of action in case of an impaired nitric oxide (NO) system remains controversial. Previous studies suggested that decreased NO bioavailability may result in the downregulation of klotho expression, but the relationship between klotho and NO remains obscure. Therefore, we investigated whether a PDE-5 inhibitor could preserve epithelial-mesenchymal transition (EMT) and relationship exists between the NO and renal klotho expression. Ten-week-old SD rats (N = 24, 200 g, male) were divided (N = 6) into four groups, which received: A LSD, L-NAME 1 mg/mL in drinking water, Udenafil 5 mg/kg subcutaneously and both for 4 weeks. Urine nitrate/nitrite, NGAL (Neutrophil gelatinase-associated lipocalin), and cGMP were measured using ELISA.
podocyte injury. 2, 3 In an animal model of kidney ischaemic-reperfusion injury, Nω-Nitro-L-arginine methyl ester hydrochloride (L-NAME) showed toxic effect on glomerulus and tubule in several animal models, such as preeclampsia, spontaneous hypertensive rat. [4] [5] [6] [7] These effects mediated via the modulation of the nitric oxide (NO) system by PDE5 inhibitors suggest that an increase in end-product in target organ can ameliorate tissue damage in several diseases. [7] [8] [9] We have previously reported that PDE-5 inhibitors can ameliorate cyclosporine A-induced renal injury.
10
The number of studies examining the role of fibroblast growth factor-23 (FGF23) and klotho in chronic kidney disease (CKD) has risen exponentially over the past decade. Tissue levels of the FGF23 coreceptor klotho declines in early CKD and this deficiency is linking to accelerated ageing, cellular senescence, vascular calcification, oxidative stress, and renal fibrosis. At present, methodological difficulties limit the utility of soluble klotho measurements, but animal studies have demonstrated the beneficial effects of klotho delivery in CKD. 11 The in vivo reduction in endogenous NO production in klotho-deficient mice is reflected by the reduced urinary excretion of NO metabolites and cGMP (an indicator of NO synthesis). 12, 13 Further, in-vitro experimental findings lend support for klotho-induced enhancement of NO production in human endothelial cells via modulation of the activity of endothelial nitric oxide synthase (eNOS), the enzyme responsible for generation of NO. 14, 15 Epithelial-mesenchymal transition (EMT) has been implicated in cancer progression and metastasis, wound healing, and the development of fibrotic disorders, including pulmonary, hepatic, and renal fibrosis. [16] [17] [18] EMT in the kidney can be induced by CKD-associated renal hypoxia, which is thought to result from a combination of structural and functional changes that include decrease in the number of capillaries, compromised peritubular blood flow resulting from glomerular injury, vasoconstriction due to changes in the levels of vasoactive factors and signaling molecules such as angiotensin II, endothelin, and NO.
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Therefore, in this study, we investigated whether PDE5 inhibition could ameliorate EMT via klotho expression in the kidney.
| RESULTS

| Comparison of the effects of a phosphodiesterase 5 inhibitor on the NO system among the groups
Urine nitrate/nitrite and cGMP levels were measured and normalized to creatinine levels to determine the success of the experimental design. The nitrate/nitrite metabolite levels showed a decreasing trend in the L-NAME and L-NAME with Udenafil groups compared to that in the control and Udenafil groups. The urine cGMP levels were 2.59 ± 0.88, 1.79 ± 0.99, 1.20 ± 0.22, and 0.69 ± 0.59 nmol/μL for the control, L-NAME, Udenafil and L-NAME with Udenafil groups, respectively (P < .05, control vs Udenafil and L-NAME with Udenafil groups) ( Figure 1A , B).
| The comparison of renal function and degree of injury among the groups
In the Udenafil group, kidney function showed a slight increase as indicated by the decrease in serum creatinine. However, other groups did not show a statistically significant change ( Figure 2 ). PCNA expression in terms of PCNA-positive tubular cells/unit area was 0.11 ± 0.06, 0.31 ± 0.14, 0.17 ± 0.02, and 0.19 ± 0.08 mL for the control, L-NAME, Udenafil, and L-NAME with Udenafil groups, respectively F I G U R E 1 Comparison among the different groups of the effects on the nitric oxide system. (A) Urine nitrate/nitrite metabolite concentration. (B) Urine cGMP concentration detected using an ELISA kit. *P < .05
The comparison of serum creatinine levels among the groups. *P < .05 (P < .05, control vs L-NAME, and L-NAME vs L-NAME with Udenafil) (Figure 3 ). The urine NGAL levels were 279.8 ± 126.8, 651.0 ± 195.3, 473.7 ± 114.9, and 326.5 ± 279.4 ng/mL for the control, L-NAME, Udenafil, and L-NAME with Udenafil groups, respectively (P < .05
control vs L-NAME and L-NAME with Udenafil) (Figure 4 ). There were no functional changes in the kidney among the groups, but acute injury to tubular cells was well established in the L-NAME group, and this damage was ameliorated by Udenafil treatment.
| The changes of epithelial-mesenchymal transition markers after treatment
α-SMA showed increased expression in the L-NAME group compared to that the L-NAME with Udenafil group (control 0.45 ± 0.02, L-NAME 0.95 ± 0.05, Udenafil 0.50 ± 0.02, and L-NAME with Udenafil 0.31 ± 0.11). E-cadherin protein expression decreased in the L-NAME group compared to that in the other groups (control 0.911 ± 0.01, L-NAME 0.36 ± 0.09, Udenafil 0.99 ± 0.01, and L-NAME with Udenafil 0.62 ± 0.03) ( Figure 5 ). Considered together with the changes in PCNA expression, these results suggest that L-NAME treatment induced EMT in the kidney and that Udenafil has a protective effect in the kidney.
| The mechanism of attenuation of epithelialmesenchymal transition after treatment
Klotho mRNA expression increased in the L-NAME with Udenafil group compared with that in the L-NAME group determined by RT-PCR (control 0.98 ± 0.01, L-NAME 0.30 ± 0.05, Udenafil 0.68 ± 0.06, and L-NAME with Udenafil 0.54 ± 0.13) ( Figure 6 ). Klotho protein density, as determined by immunohistochemical stain, showed the same trend among the groups. After treatment with Udenafil, klotho however, eNOS protein expression in the L-NAME and L-NAME with Udenafil groups was not significantly different from that in the control ( Figure 7 ).
| DISCUSSION
Epithelial-mesenchymal transition was induced by several factors in cancer cell and nitric oxide system had epithelial-mesenchymal transition in this study using L-NAME was not established well, however, Seccia etc. proved that endothelin-1 drives epithelial-mesenchymal transition in hypertensive nephroangiosclerosis. 20 L-NAME also can make hypertension, podocyte injury, and tubular damage in hypertensive rat model. There is no study measuring EMT markers in the kidney using L-NAME toxicity until now, we can confirm the change of E-cadherin, alpha SMA, PCNA in the tubular cell after treating L-NAME. Therefore, we can use L-NAME induced tubular injury model for EMT study. 27 We focused on klotho expression in our animal model to prove the mechanism of PDE5 inhibition under conditions of NO system deterioration.
Our animal model was designed to demonstrate the effect of cGMP increase under impaired NO donation conditions in kidney tissue. One study showed the effects of peroral sildenafil administration in the macaque monkey (Macaca fascicularis) by performing chemical analysis
Comparison of the urine NGAL/Cr ratio among the groups. *P < .05
Comparisons of kidney alpha SMA and E-cadherin expression among the groups as measured by western blot. *P < .05
of plasma and cerebrospinal fluid (CSF) using liquid chromatography coupled with tandem mass spectrometry. The results showed that drug levels in the CSF were high enough to inhibit PDE5 activity, which was also demonstrated by the significant increases in CSF cGMP levels.
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In our animal model, urine cGMP levels decreased in the L-NAME with
Udenafil group compared with that in the other groups; although the cGMP level in the kidney tissue was not quantified, the effect of PDE5
inhibitor was enough to enable assessment of group differences.
CKD is a prevalent disease affecting 13% of adults in the United States, with 8% having an estimated glomerular filtration rate (eGFR) of <60 mL/min per 1.73 m 2 according to the National Health and Nutrition Examination Survey (1999) (2000) (2001) (2002) (2003) (2004) . 29 In recent years, considerable evidence has accumulated to suggest that CKD is a state of relative renal and systemic NO deficiency caused by a combination of decreased renal and vascular NO production and increased NO bioinactivation. 30 Because of the important protective role played by NO in the health of both renal and cardiovascular systems, it is likely that a deficit in NO will accelerate CKD progression and increase cardiovascular risk, making the NO pathway a promising therapeutic target. 31 The relationship between the NO system and klotho was not clearly elucidated in this study, but we showed that chronic NOS inhibition markedly reduced renal klotho protein expression. Moreover, a previous study showed that treatment with atorvastatin or pitavastatin completely prevented the reduction of klotho expression induced by NOS inhibition. 32 Klotho protein exists in both a secreted and a membrane form. Its extracellular domain can be shed from the cell surface angiotensin-aldosterone system. 33 Soluble klotho and active vitamin D levels decrease and FGF23 levels increase at early CKD stages, whereas parathyroid hormone levels increase at more advanced CKD stages. 34 In the ischaemia-reperfusion injury rodent model, klotho in the kidneys, urine, and blood decreased; klotho levels in all these organs were restored upon recovery. Reduction in kidney and plasma klotho levels occurred earlier than reduction of NGAL, a known biomarker of kidney injury. 35 Our study also showed that klotho mRNA and protein levels in the kidney were inversely correlated with NGAL expression, although the time sequence of this phenomenon was not clear. Klotho might have some beneficial effect on L-NAME-induced kidney injury.
Eryptosis, the suicidal death of erythrocytes, is characterized by erythrocyte shrinkage, blebbing, and phospholipid scrambling of the cell membrane. Eryptosis is enhanced in mouse models of sickle cell anemia and thalassemia, as well as in mice lacking functional annexin 7, cGMP-dependent protein kinase type I, AMP-activated protein kinase, Janus kinase 3, anion exchanger 1, adenomatous polyposis coli, or klotho. 36,37 Therefore, we postulated this mechanism was that deficiencies of cGMP and klotho can induce cell death and have interrelationship. Our study results showed that induction of cGMP independent of NO can restore klotho expression and reverse renal injury induced by L-NAME.
The origin and precise molecular and functional differences between mesenchymal cells and fibroblasts during EMT are not
Comparison of eNOS protein expression in the kidney among the groups. (A) Control, (B) L-NAME, (C) Udenafil, (D) L-NAME with Udenafil. *P < .05
completely understood. Renal fibrosis is a pathological condition characterized by excessive accumulation of extracellular matrix and it is a common pathway for the progression of different renal diseases.
Transforming growth factor-β1 (TGF-β1) is implicated in the pathogenesis of fibrosis in both glomerular and interstitial compartments of the kidney. Klotho acts as an endogenous inhibitor of multiple growth factors including TGF-β1. 38, 39 In one study, renal fibrosis was induced by unilateral ureteral obstruction (UUO) in mice with reduced klotho expression (kl/+ mice) and they were then compared with wild-type mice. The UUO kidneys from kl/+ mice had significantly higher levels of fibrosis markers such as α-SMA, fibronectin, and TGF-β1 than those from wild-type mice. 40 E-cadherin, a key component of cell-cell adhesion junctions, is essential for the formation of epithelia during embryonic development and for the maintenance of adult epithelial homeostasis; its loss is associated with increased tumor cell invasiveness. 41 L-NAME-induced renal injury increased the levels of EMT markers such as PCNA and α-SMA, and decreased the levels of anti-EMT markers such as E-cadherin. 42 Thus, EMT can be improved by a PDE5 inhibitor treatment via klotho attenuation.
Kidney fibrosis induced by EMT was aggravated by reduced klotho levels, which can suppress TNF-α expression and attenuate NF-κB activation. 43, 44 TGF-β1 mediated upregulation of PDE4 activity promotes EMT in alveolar epithelial cells in lung tissue. 45 One study showed that the klotho-induced reversal of EMT in SiHa cells is associated with downregulation of transcriptional factor Slug/Twist and resultant upregulation of E-cadherin. 46 We also could demonstrate the same change of TWIST 1,2 mRNA (EMT signaling markers) in the kidney after treatment (data not shown). Until now, there is no study has demonstrated a direct connection between renal EMT and PDEs.
We postulate that the core molecule of attenuating EMT after tubular injury involved might be klotho, because eNOS expression (NO system) was not changed after treatment (Figure 8 ).
In conclusion, we suggest that, in a poor NO environment, PDE5
inhibitors can have protective effect on EMT via the klotho pathway independent of NO system.
| MATERIALS AND METHODS
| Animals
Ten-week-old male Sprague-Dawley rats (body weight 200-250 g)
were housed with standard chow and tap water available ad libitum.
All animal procedures and care protocols were approved by Yonsei University at Wonju Campus IACUC (Institutional Animal Care and Use Committee).
| Animal groups and experimental design
The 10-week-old male Sprague-Dawley rats (N = 24; weight 200 g)
were divided into four groups, which received the following treatments for 4 weeks: a low salt diet (control group; N = 6); L-NAME 1 mg/mL in drinking water (L-NAME group; N = 6); [47] [48] [49] Udenafil 5 mg subcutaneously (SQ) (Udenafil group; N = 6); and both L-NAME and udenafil (L-NAME and udenafil group; N = 6). The experimental drugs used were L-NAME (Nω-Nitro-L-arginine methyl ester hydrochloride, Sigma-Aldrich Co., St. Louis, MO, USA) and Udenafil (Zydena, Dong-A Pharmaceutical Co., Seoul, Korea), a PDE-5 inhibitor. Low salt diet can increase sensitivity of renal injury, because its activation of renin-angiotensin system can augment L-NAME induced tubular cell damage. We decided the dosage and duration of L-NAME and udenafil following several other study protocols. 
| Biochemical markers
On day 28, serum creatinine was measured using a kinetic colorimetric assay with the Modular equipment (Hitachi High-Technologies Corporation, Tokyo, Japan). Urine nitrate/nitrite and cGMP levels were measured using an ELISA kit (R&D Systems, Minneapolis, USA) according to the manufacturer's instructions. Urine neutrophil gelatinase-associated lipocalin (NGAL) levels were also measured using an ELISA kit (Abcam, Cambridge, UK).
| Immunohistochemistry
Kidney tissue blocks embedded in paraffin were prepared as 5-μm 
| Statistical analyses
The SPSS version 12.0 and Graphpad Prism 5 program was used for statistical comparisons and making graph. The non-parametric
Kruskal-Wallis and Mann-Whitney test were used. A P value less than
.05 was considered significant.
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